Connection & GIST Education at the GIST Day of Learning Minnesota
A great community and an expert team of GIST specialist made up an amazing GIST Day of Learning at Mayo Clinic in Minnesota this October.
GIST Summit / GIST Day of Learning 2026
The GIST Summit 2026, held on March 21, at MD Anderson Cancer Center in Houston was a highly successful collaborative event that brought together approximately 125 patients, caregivers, medical professionals, and subject matter experts from across the country.
Histotripsy: What Patients Need to Know
Let's talk about histotripsy and sarcoma - what is the potential of this new procedure?
GIST Day of Learning Boston 2025
Saturday, September 27, 2025, The Life Raft Group hosted a GIST Day of Learning (GDOL) at Dana-Farber Cancer Institute in Boston.
GIST Summit 2025/GDOL Texas Presentations & Photo Gallery
GIST Summit 2025/GDOL Texas was held at MD Anderson Cancer Center and presentations and photo gallery are now available.
Clinical Trials & Nutrition
Nutrition is important to keep in mind during any cancer treatment, but especially during a clinical trial.
Join the LRG’s Vision – Thriving Together in 2023
The Life Raft Group is thankful to those who so generously supported us in 2022 and we hope you continue to support our new initiatives in 2023. #thrivingtogether
Executive Director Sara Rothschild Participates in Medscape CME on GIST
LRG Executive Director Sara Rothschild took part in a CME course produced by Medscape titled 'Improving Outcomes & Quality of Life in Advanced GIST: Discussing the Patient Journey and the Latest Data.'
Surgical Considerations in GIST
In this webinar. Dr. Andrew Blakely, surgical oncologist, National Cancer Institute, Center for Cancer Research, NIH, discussed the basics of surgical removal of primary GISTs and considerations in multimetastatic disease.
The Emerging Role of Circulating Tumor DNA in Gastrointestinal Stromal Tumor
In this webinar, “The Emerging Role of Circulating Tumor DNA in Gastrointestinal Stromal Tumor”, Dr. Bialick discussed recent data looking at treatment outcomes based off KIT resistant mutations identified by circulating tumor DNA in patients with GIST.